Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations

Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jan 8, 2010 - Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) announced today the appointment of Drayton Virkler as senior director of the Talecris Investor Relations department.

Virkler's diverse skill set combines knowledge and experience in the areas of pharmaceutical operations, sales and marketing, commercial development and finance. In his new position, Virkler will leverage his expertise in these critical areas to inform investors about Talecris' plasma-derived protein therapies.

"Drayton's extensive knowledge of our business will provide investors with the necessary depth of understanding to help inform their investment decisions," said John Hanson, Talecris' Chief Financial Officer. "Through Drayton's leadership, Talecris will establish and build a dynamic investor relations program that is responsive to our investors."

In his new role, Virkler will be responsible for building and leading Talecris' Investor Relations department, including communications with the analyst and investor communities and all other shareholder communications. Virkler assumed his new role on Jan. 4, transitioning from the position of director, U.S. product management for the Talecris Hypermune franchise, which develops products to treat and prevent a wide range of potentially fatal infections. Prior to his arrival at Talecris, Virkler spent five years at GlaxoSmithKline in positions of increasing responsibility, including senior product manager for the migraine marketing team and product director for ADVAIR marketing. Before his tenure at GlaxoSmithKline, Virkler served as a research and development chemist at a specialty chemical manufacturer.

Virkler earned his MBA at Duke University and his bachelor of science degree at Washington and Lee University.

Talecris investor information is available at www.talecris.com/investor-relations. The Talecris Investor Relations department can be reached directly at 919-316-2300 or at [email protected]

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis.

Contact: Talecris Biotherapeutics
Becky Levine, 919-316-6590
Fax: 919-316-6673
[email protected]

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.